Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | Slc35g2 | Rat | 17beta-estradiol | increases expression | ISO | Slc35g2 (Mus musculus) | 6480464 | Estradiol results in increased expression of SLC35G2 mRNA | CTD | PMID:39298647 | Slc35g2 | Rat | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC35G2 mRNA | CTD | PMID:26238291 | Slc35g2 | Rat | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC35G2 mRNA | CTD | PMID:32109520 | Slc35g2 | Rat | 2-methylcholine | affects expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | beta-methylcholine affects the expression of SLC35G2 mRNA | CTD | PMID:21179406 | Slc35g2 | Rat | aflatoxin B1 | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased expression of SLC35G2 mRNA | CTD | PMID:21641981|PMID:27153756 | Slc35g2 | Rat | all-trans-retinoic acid | decreases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of SLC35G2 mRNA | CTD | PMID:33167477 | Slc35g2 | Rat | amphetamine | increases expression | EXP | | 6480464 | Amphetamine results in increased expression of SLC35G2 mRNA | CTD | PMID:30779732 | Slc35g2 | Rat | aristolochic acid A | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | aristolochic acid I results in increased expression of SLC35G2 mRNA | CTD | PMID:33212167 | Slc35g2 | Rat | benzo[a]pyrene | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased expression of SLC35G2 mRNA | CTD | PMID:20064835|PMID:20106945|PMID:21632981|PMID:22316170|PMID:26238291 | Slc35g2 | Rat | benzo[a]pyrene | affects methylation | ISO | SLC35G2 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of SLC35G2 promoter | CTD | PMID:27901495 | Slc35g2 | Rat | benzo[a]pyrene | decreases methylation | ISO | SLC35G2 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased methylation of SLC35G2 5' UTR | CTD | PMID:27901495 | Slc35g2 | Rat | benzo[a]pyrene | multiple interactions | ISO | Slc35g2 (Mus musculus) | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of more ... | CTD | PMID:27858113 | Slc35g2 | Rat | benzo[a]pyrene diol epoxide I | decreases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SLC35G2 mRNA | CTD | PMID:19150397 | Slc35g2 | Rat | benzo[b]fluoranthene | multiple interactions | ISO | Slc35g2 (Mus musculus) | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of more ... | CTD | PMID:27858113 | Slc35g2 | Rat | beta-lapachone | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | beta-lapachone results in increased expression of SLC35G2 mRNA | CTD | PMID:38218311 | Slc35g2 | Rat | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of SLC35G2 mRNA | CTD | PMID:25181051 | Slc35g2 | Rat | Butylbenzyl phthalate | increases methylation | ISO | Slc35g2 (Mus musculus) | 6480464 | butylbenzyl phthalate results in increased methylation of SLC35G2 intron | CTD | PMID:28392331 | Slc35g2 | Rat | cadmium dichloride | increases expression | EXP | | 6480464 | Cadmium Chloride results in increased expression of SLC35G2 mRNA | CTD | PMID:33453195 | Slc35g2 | Rat | caffeine | decreases phosphorylation | ISO | SLC35G2 (Homo sapiens) | 6480464 | Caffeine results in decreased phosphorylation of SLC35G2 protein | CTD | PMID:35688186 | Slc35g2 | Rat | carbamazepine | affects expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Carbamazepine affects the expression of SLC35G2 mRNA | CTD | PMID:25979313 | Slc35g2 | Rat | chrysene | multiple interactions | ISO | Slc35g2 (Mus musculus) | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of more ... | CTD | PMID:27858113 | Slc35g2 | Rat | copper atom | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of SLC35G2 mRNA | CTD | PMID:20971185 | Slc35g2 | Rat | copper(0) | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of SLC35G2 mRNA | CTD | PMID:20971185 | Slc35g2 | Rat | copper(II) chloride | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | cupric chloride results in increased expression of SLC35G2 mRNA | CTD | PMID:38568856 | Slc35g2 | Rat | copper(II) sulfate | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of SLC35G2 mRNA | CTD | PMID:19549813 | Slc35g2 | Rat | coumarin | increases phosphorylation | ISO | SLC35G2 (Homo sapiens) | 6480464 | coumarin results in increased phosphorylation of SLC35G2 protein | CTD | PMID:35688186 | Slc35g2 | Rat | cyclosporin A | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of SLC35G2 mRNA | CTD | PMID:20106945|PMID:25562108 | Slc35g2 | Rat | cylindrospermopsin | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | cylindrospermopsin results in increased expression of SLC35G2 mRNA | CTD | PMID:24921660 | Slc35g2 | Rat | Dibutyl phosphate | affects expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | di-n-butylphosphoric acid affects the expression of SLC35G2 mRNA | CTD | PMID:37042841 | Slc35g2 | Rat | diuron | decreases expression | EXP | | 6480464 | Diuron results in decreased expression of SLC35G2 mRNA | CTD | PMID:21551480 | Slc35g2 | Rat | dorsomorphin | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression more ... | CTD | PMID:27188386 | Slc35g2 | Rat | entinostat | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | entinostat results in increased expression of SLC35G2 mRNA | CTD | PMID:26272509 | Slc35g2 | Rat | entinostat | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression more ... | CTD | PMID:27188386 | Slc35g2 | Rat | FR900359 | decreases phosphorylation | ISO | SLC35G2 (Homo sapiens) | 6480464 | FR900359 results in decreased phosphorylation of SLC35G2 protein | CTD | PMID:37730182 | Slc35g2 | Rat | hydrogen peroxide | affects expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of SLC35G2 mRNA | CTD | PMID:20044591 | Slc35g2 | Rat | lead(0) | affects expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Lead affects the expression of SLC35G2 mRNA | CTD | PMID:28903495 | Slc35g2 | Rat | leflunomide | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | leflunomide results in increased expression of SLC35G2 mRNA | CTD | PMID:28988120 | Slc35g2 | Rat | mercury dibromide | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | mercuric bromide results in increased expression of SLC35G2 mRNA | CTD | PMID:26272509 | Slc35g2 | Rat | mercury dibromide | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased more ... | CTD | PMID:27188386 | Slc35g2 | Rat | methylmercury chloride | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | methylmercuric chloride results in increased expression of SLC35G2 mRNA | CTD | PMID:28001369 | Slc35g2 | Rat | p-chloromercuribenzoic acid | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | p-Chloromercuribenzoic Acid results in increased expression of SLC35G2 mRNA | CTD | PMID:26272509 | Slc35g2 | Rat | p-chloromercuribenzoic acid | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased more ... | CTD | PMID:27188386 | Slc35g2 | Rat | panobinostat | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression more ... | CTD | PMID:27188386 | Slc35g2 | Rat | perfluorohexanesulfonic acid | increases expression | ISO | Slc35g2 (Mus musculus) | 6480464 | perfluorohexanesulfonic acid results in increased expression of SLC35G2 mRNA | CTD | PMID:37995155 | Slc35g2 | Rat | phenylmercury acetate | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in increased expression of SLC35G2 mRNA | CTD | PMID:26272509 | Slc35g2 | Rat | phenylmercury acetate | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased more ... | CTD | PMID:27188386 | Slc35g2 | Rat | quercetin | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Quercetin results in increased expression of SLC35G2 mRNA | CTD | PMID:21632981 | Slc35g2 | Rat | resveratrol | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of SLC35G2 mRNA | CTD | PMID:23557933 | Slc35g2 | Rat | SB 431542 | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression more ... | CTD | PMID:27188386 | Slc35g2 | Rat | silicon dioxide | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Silicon Dioxide analog results in increased expression of SLC35G2 mRNA | CTD | PMID:25895662 | Slc35g2 | Rat | sodium arsenite | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | sodium arsenite results in increased expression of SLC35G2 mRNA | CTD | PMID:21281968|PMID:38568856 | Slc35g2 | Rat | Soman | decreases expression | EXP | | 6480464 | Soman results in decreased expression of SLC35G2 mRNA | CTD | PMID:19281266 | Slc35g2 | Rat | sulforaphane | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | sulforaphane results in increased expression of SLC35G2 mRNA | CTD | PMID:31838189 | Slc35g2 | Rat | tert-butyl hydroperoxide | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | tert-Butylhydroperoxide results in increased expression of SLC35G2 mRNA | CTD | PMID:15336504 | Slc35g2 | Rat | tetraphene | multiple interactions | ISO | Slc35g2 (Mus musculus) | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of more ... | CTD | PMID:27858113 | Slc35g2 | Rat | thapsigargin | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Thapsigargin results in increased expression of SLC35G2 mRNA | CTD | PMID:29453283 | Slc35g2 | Rat | titanium dioxide | decreases methylation | ISO | Slc35g2 (Mus musculus) | 6480464 | titanium dioxide results in decreased methylation of SLC35G2 gene | CTD | PMID:35295148 | Slc35g2 | Rat | topotecan | affects response to substance | ISO | SLC35G2 (Homo sapiens) | 6480464 | SLC35G2 protein affects the susceptibility to Topotecan | CTD | PMID:16217747 | Slc35g2 | Rat | trichloroethene | increases expression | EXP | | 6480464 | Trichloroethylene results in increased expression of SLC35G2 mRNA | CTD | PMID:33387578 | Slc35g2 | Rat | trichostatin A | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | trichostatin A results in increased expression of SLC35G2 mRNA | CTD | PMID:24935251 | Slc35g2 | Rat | triptonide | increases expression | ISO | Slc35g2 (Mus musculus) | 6480464 | triptonide results in increased expression of SLC35G2 mRNA | CTD | PMID:33045310 | Slc35g2 | Rat | valproic acid | affects expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of SLC35G2 mRNA | CTD | PMID:25979313 | Slc35g2 | Rat | valproic acid | multiple interactions | ISO | SLC35G2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased more ... | CTD | PMID:27188386 | Slc35g2 | Rat | valproic acid | increases expression | ISO | SLC35G2 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of SLC35G2 mRNA | CTD | PMID:23179753|PMID:24383497|PMID:24935251|PMID:26272509|PMID:28001369|PMID:29154799 | Slc35g2 | Rat | zalcitabine | multiple interactions | EXP | | 6480464 | [gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of SLC35G2 more ... | CTD | PMID:18606552 | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






















